Mashal Robert purchased $118K of NUVB (indirect holdings)

Mashal Robert purchased 25,000 indirectly-held shares of Nuvation Bio Inc. (NUVB) at $4.73 ($0.12M total) on 2026-06-09.

Original reporting
SEC EDGAR · Mashal Robert
Published Jun 12, 2026, 12:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NUVB
Bullish
medium confidence
Mentioned
$NUVB
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVBBullishLow
01

Why it matters

A director open-market purchase can modestly improve sentiment, but the disclosure alone does not change the company’s operating outlook.

02

Market read

Traders may treat the insider buy as a small bullish input, but it is unlikely to drive a sustained repricing without additional fundamental catalysts.

03

What to watch

Insider buys can be offset by other insider sales or dilution/financing needs; traders should check for concurrent Form 4 activity and any upcoming corporate events not mentioned here.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-11 for a 2026-06-09 open-market purchase

Background

The article reports an SEC Form 4 insider transaction for Nuvation Bio, filed via EDGAR.

Company-level read

Ticker impact

$NUVBBullishMedium confidence
Context

Director Mashal Robert bought 25,000 shares of Nuvation Bio at $4.73/share via an open-market purchase disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider purchases can support bullish sentiment, but this is a single director transaction with no accompanying operational/regulatory update in the text.

Market effects

No clear sector read-through; this is a company-specific insider transaction without broader industry information.

None indicated.

None indicated.

Counterpoint

The purchase may be routine or driven by personal liquidity/compensation timing; the article notes no pre-arranged 10b5-1 plan, but that still doesn’t confirm conviction about near-term fundamentals.

Key entities

  • Nuvation Bio Inc.

    Subject of the SEC Form 4 insider transaction disclosed in the article.

  • Mashal Robert

    Director who purchased 25,000 shares on 2026-06-09 at $4.73/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NUVBMed

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Inc. (NUVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed

$NUVBHighAI 8/10

Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio (NYSE: NUVB) reported Q3 2026 revenue of $45.0M, with $27.5M from IBTROZI®. IBTROZI, a ROS1 TKI, is the market leader in new patient starts and total active patients. FDA approved a label update for IBTROZI, reflecting a 49.7-month median duration of response. The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma. The company had $663.4M in cash as of September 30, 2026.

$NUVBMed

Nuvation Bio earnings in focus as drug launch faces first test

Nuvation Bio Inc. reports Q3 earnings, with analysts expecting a loss of 12 cents per share on $35.1M revenue. IBTROZI, its lung cancer drug, is key, with revenue and patient mix under scrutiny. The stock has fallen 25% in 3 months, trading near its 52-week low. Analysts have a mean price target of $13, implying 177% upside from the current $4.69 price.

$NUVBMedAI 8/10

Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting

Nuvation Bio (NYSE: NUVB) will present updated Phase 2 results and ongoing trial overviews for safusidenib, its investigational IDH1 inhibitor, at the 2026 SNO Annual Meeting. The presentation includes additional data from the Phase 2 J201 study, previously announced in July 2026. Safusidenib is being studied for IDH1-mutant glioma, a type of brain cancer with significant unmet medical needs.

$NUVBMedAI 8/10

Nuvation Bio expands glioma drug trial to six European nations

Nuvation Bio (NYSE:NUVB) expanded its Phase 3 SIGMA trial of safusidenib to six European countries, adding to existing sites in the U.S., Australia, China, Canada, and Japan. The study evaluates safusidenib as maintenance therapy for IDH1-mutant astrocytoma, with a primary endpoint of progression-free survival. The trial plans to enroll 300 patients, with an exploratory cohort of 40. The FDA granted Fast Track Designation to safusidenib in August 2026.